Drug Trial Radar · NCT04231513
A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Apr 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Dec 16, 2019
Primary completion
Mar 9, 2023
Study completion Mar 9, 2023
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Jan 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the safety and tolerability of single and multiple intravenous infusions of E2814 in healthy adult participants.
Conditions
- Healthy Volunteers
Interventions
E2814Drug
E2814, intravenous infusion.
E2814-matched placeboDrug
E2814-matched placebo, intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SAD, Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Up to 113 days
- SAD, Number of Participants With Clinically Significant Laboratory ValuesTime frame: Up to 113 days
- SAD, Number of Participants With Clinically Significant Vital Signs ValuesTime frame: Up to 113 days
- SAD, Number of Participants With Clinically Significant Electrocardiogram (ECG) FindingsTime frame: Up to 113 days
- MAD, Number of Participants With TEAEs and SAEsTime frame: Up to 169 days
- MAD, Number of Participants With Clinically Significant Laboratory ValuesTime frame: Up to 169 days
- MAD, Number of Participants With Clinically Significant Vital Signs ValuesTime frame: Up to 169 days
- MAD, Number of Participants With Clinically Significant ECG FindingsTime frame: Up to 169 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
California Clinical Trials Medical Group/Parexel International
Glendale, California
Worldwide Clinical Trials
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.